Back
 OJAnes  Vol.4 No.9 , September 2014
Sugammadex in the Management of Sinus Tachycardia after Rocuronium Administration: A Case Report
Abstract: In rare cases, rocuronium has been associated with dose-related tachycardia, probably by a cardiac muscarinic M2 receptor blockade mechanism. We report the case of a 30-year-old female who underwent excision of a branchial cyst under general anesthesia. This patient presented an episode of sinus tachycardia (130 bpm) shortly after anesthesia induction with propofol, sufentanyl, and rocuronium. Tachycardia could not be explained by any cause other than the use of rocuronium, which was reverted with sugammadex. Two minutes after sugammadex administration, heart rate normalized, corroborating our hypothesis that rocuronium induced the sinus tachycardia observed in our patient. The patient recovered well from the anesthetic-surgical procedure and showed no further cardiovascular, ventilatory, or neurological changes, being transferred to the post-anesthesia care unit, and finally discharged to the ward.
Cite this paper: Orioli Guimarães, E. , Saldanha, M. , Fortes, T. , Grisolia, M. , Miranda, M. and Alves Bersot, C. (2014) Sugammadex in the Management of Sinus Tachycardia after Rocuronium Administration: A Case Report. Open Journal of Anesthesiology, 4, 203-206. doi: 10.4236/ojanes.2014.49029.
References

[1]   Stevens, J.B., Hexker, R.B., Talbot, J.C. and Walker, S.C. (1997) The Haemodynamic Effects of Rocuronium and Vecuronium Are Different under Balanced Anaesthesia. Acta Anaesthesiologica Scandinavica, 41, 502-505.
http://dx.doi.org/10.1111/j.1399-6576.1997.tb04731.x

[2]   Appadu, B.L. and Lammbert, D.G. (1994) Studies on the Interaction of Steroidal Neuromuscular Blocking Drugs with Cardiac Muscarinic Receptors. British Journal of Anaesthesia, 72, 86-88.
http://dx.doi.org/10.1093/bja/72.1.86

[3]   Dunlap, J. and Brown, J.H. (1983) Heterogeneity of Binding Sites on Cardiac Muscarinic Receptors Induced by Neuromuscular Blocking Agents Gallamine and Pancuronium. Molecular Pharmacology, 24, 15-22.

[4]   Sorensen, M.K., Bretlau, C., Gatke, M.R., Sorensen, A.M. and Rasmussen, L.S. (2012) Rapid Sequence Induction and Intubation with Rocuronium-Sugammadex Compared with Succinylcholine: A Randomized Trial. British Journal of Anaesthesia, 108, 682-689.
http://dx.doi.org/10.1093/bja/aer503

[5]   Levy, J.H., Davis, G.K., Duggan, J. and Szlam, F. (1994) Determination of the Hemodynamics and Histamine Release of Rocuronium (Org 9426) When Administered in Increased Doses under N2O/O2-Sufentanil Anesthesia. Anesthesia & Analgesia, 78, 318-321.
http://dx.doi.org/10.1213/00000539-199402000-00020

[6]   Bhananker, S.M., O’Donnell, J.T., Salemi, J.R. and Bishop, M.J. (2005) The Risk of Anaphylactic Reactions to Rocuronium in the United States Is Comparable to That of Vecuronium: An Analysis of Food and Drug Administration Reporting of Adverse Events. Anesthesia & Analgesia, 101, 819-822.
http://dx.doi.org/10.1213/01.ANE.0000175213.87556.D8

[7]   Simons, F.E., Ardusso, L.R., Bilò, M.B., El-Gamal, Y.M., Leford, D.K., Ring, J., Sanchez-Borges, M., Senna, G.E., Sheikh, A. and Thong, B.Y. (2011) World Allergy Organization Guidelines for the Assessment and Management of Anaphylaxis. World Allergy Organization Journal, 4, 13-37.
http://dx.doi.org/10.1097/WOX.0b013e318211496c

[8]   McDonnell, N.J., Pavy, T.J., Green, L.K. and Platt, P.R. (2011) Sugammadex in the Management of Rocuronium-Induced Anaphylaxis. British Journal of Anaesthesia, 106, 199-201.
http://dx.doi.org/10.1093/bja/aeq366

[9]   Kawano, T., Tamura, T., Hamaguchi, M., Yatabe, T., Yamashita, K. and Yokoyama, M. (2012) Successful Management of Rocuronium-Induced Anaphylactic Reactions with Sugammadex: A Case Report. Journal of Clinical Anesthesia, 24, 62-64.
http://dx.doi.org/10.1016/j.jclinane.2011.04.015

 
 
Top